UA125585C2 - Анти-il-22r-антитіла - Google Patents

Анти-il-22r-антитіла Download PDF

Info

Publication number
UA125585C2
UA125585C2 UAA201901458A UAA201901458A UA125585C2 UA 125585 C2 UA125585 C2 UA 125585C2 UA A201901458 A UAA201901458 A UA A201901458A UA A201901458 A UAA201901458 A UA A201901458A UA 125585 C2 UA125585 C2 UA 125585C2
Authority
UA
Ukraine
Prior art keywords
antibody
antibodies
antigen
amino acid
human
Prior art date
Application number
UAA201901458A
Other languages
English (en)
Ukrainian (uk)
Inventor
Крістоф Фредерік Джером Бланхетот
Кристоф Фредерик Джером Бланхетот
Біргітта Урсьо
Биргитта УРСЁ
Тіне Скак-Нільсен
Тине Скак-Нильсен
Малене Бертельсен
дер Вонінг Себастьян ван
дер Вонинг Себастьян ван
Майкл СОНДЕРС
Хард Йоханнес Йозеф Вільхельмус де
ХАРД Йоханнес Йозеф Вильхельмус ДЕ
Original Assignee
Ардженкс Бвба
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ардженкс Бвба filed Critical Ардженкс Бвба
Publication of UA125585C2 publication Critical patent/UA125585C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
UAA201901458A 2016-07-15 2017-07-14 Анти-il-22r-антитіла UA125585C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1612337.4A GB201612337D0 (en) 2016-07-15 2016-07-15 Ant-il-22r antibodies
PCT/EP2017/067923 WO2018011420A1 (en) 2016-07-15 2017-07-14 Anti-il-22r antibodies

Publications (1)

Publication Number Publication Date
UA125585C2 true UA125585C2 (uk) 2022-04-27

Family

ID=56890507

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201901458A UA125585C2 (uk) 2016-07-15 2017-07-14 Анти-il-22r-антитіла

Country Status (27)

Country Link
US (4) US10696741B2 (enExample)
EP (2) EP4023674A3 (enExample)
JP (1) JP7163275B2 (enExample)
KR (2) KR102571012B1 (enExample)
CN (1) CN109641966B (enExample)
AU (1) AU2017296094B2 (enExample)
BR (1) BR112019000788A2 (enExample)
CA (1) CA3024370A1 (enExample)
CY (1) CY1125041T1 (enExample)
DK (1) DK3484921T3 (enExample)
ES (1) ES2903412T3 (enExample)
GB (1) GB201612337D0 (enExample)
HR (1) HRP20220197T1 (enExample)
HU (1) HUE057615T2 (enExample)
IL (1) IL264262B2 (enExample)
LT (1) LT3484921T (enExample)
MX (1) MX2019000539A (enExample)
MY (1) MY197821A (enExample)
PL (1) PL3484921T3 (enExample)
PT (1) PT3484921T (enExample)
RS (1) RS62884B1 (enExample)
RU (1) RU2758721C2 (enExample)
SA (1) SA519400856B1 (enExample)
SG (1) SG11201900128XA (enExample)
SI (1) SI3484921T1 (enExample)
UA (1) UA125585C2 (enExample)
WO (1) WO2018011420A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
CN112292396A (zh) 2018-06-05 2021-01-29 生物蛋白有限公司 抗il-22抗体，抗体片段，其免疫结合物及其用途
CN110302363B (zh) * 2019-07-04 2020-10-09 北京大学第三医院（北京大学第三临床医学院） Il-22作为制备治疗pcos药物的应用及药物制剂
JP7789368B2 (ja) * 2020-05-29 2025-12-22 学校法人 久留米大学 炎症性腸疾患に対する治療用抗体
EP4531804A1 (en) 2022-06-03 2025-04-09 LEO Pharma A/S Liquid formulation of il-22r antibody
WO2024184333A1 (en) 2023-03-08 2024-09-12 Leo Pharma A/S Il-22r antibody for use in treating atopic dermatitis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
BRPI0408683A (pt) * 2003-03-24 2006-03-28 Zymogenetics Inc métodos de produzir um anticorpo para um polipeptìdeo, anticorpo ou fragmento de anticorpo, método para reduzir ou inibir a proliferação ou diferenciação induzida por il-22 ou induzida por il-20 de células hematopoiéticas e progenitores de células hematopoiéticas, uso de um anticorpo, de uma composição de um anticorpo ou fragmento de anticorpo, uso de um antagonista de il-22 ou il-20, uso de um antagonista de il-22ra
JP4898691B2 (ja) 2004-10-22 2012-03-21 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法
NZ621483A (en) * 2005-12-02 2015-10-30 Genentech Inc Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
IN2012DN03362A (enExample) * 2009-11-19 2015-10-23 Merck Serono Sa
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
GB2504139B (en) * 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
EP2791171A1 (en) * 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
EP2977386A1 (en) 2012-08-31 2016-01-27 Argen-X Nv Method for producing antibody molecules having inter-species, intra-target cross-reactivity
WO2014133728A2 (en) * 2013-03-01 2014-09-04 Albert Einstein College Of Medicine Of Yeshiva University Hhla2 as a novel inhibitor of human immune system and uses thereof
CN105601739B (zh) * 2016-02-22 2019-01-18 王晨辉 一种人源化抗白介素22基因工程抗体及其应用
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies

Also Published As

Publication number Publication date
SG11201900128XA (en) 2019-02-27
IL264262B2 (en) 2024-11-01
CN109641966B (zh) 2022-08-23
MX2019000539A (es) 2019-10-04
EP3484921A1 (en) 2019-05-22
ES2903412T3 (es) 2022-04-01
WO2018011420A1 (en) 2018-01-18
AU2017296094B2 (en) 2024-02-01
IL264262B1 (en) 2024-07-01
KR20230128137A (ko) 2023-09-01
RS62884B1 (sr) 2022-03-31
US20230088269A1 (en) 2023-03-23
CA3024370A1 (en) 2018-01-18
CN109641966A (zh) 2019-04-16
HUE057615T2 (hu) 2022-05-28
LT3484921T (lt) 2022-01-10
NZ748737A (en) 2025-06-27
US20200157207A1 (en) 2020-05-21
KR102571012B1 (ko) 2023-08-24
BR112019000788A2 (pt) 2019-07-02
EP3484921B1 (en) 2021-11-17
GB201612337D0 (en) 2016-08-31
US11447544B2 (en) 2022-09-20
MY197821A (en) 2023-07-18
KR20190026766A (ko) 2019-03-13
PT3484921T (pt) 2022-01-26
JP7163275B2 (ja) 2022-10-31
US20200216528A1 (en) 2020-07-09
SA519400856B1 (ar) 2022-10-25
EP4023674A2 (en) 2022-07-06
IL264262A (en) 2019-02-28
HRP20220197T1 (hr) 2022-04-29
US10696741B2 (en) 2020-06-30
AU2017296094A1 (en) 2018-12-13
SI3484921T1 (sl) 2022-02-28
JP2019528046A (ja) 2019-10-10
EP4023674A3 (en) 2022-10-05
RU2019103991A (ru) 2020-08-17
PL3484921T3 (pl) 2022-03-28
US11261246B2 (en) 2022-03-01
CY1125041T1 (el) 2023-03-24
US20190127459A1 (en) 2019-05-02
RU2758721C2 (ru) 2021-11-01
RU2019103991A3 (enExample) 2021-04-29
DK3484921T3 (da) 2022-02-07

Similar Documents

Publication Publication Date Title
UA125585C2 (uk) Анти-il-22r-антитіла
US20210277094A9 (en) Rsv-specific binding molecule
KR102879500B1 (ko) Wnt 시그널링 작용제 분자
WO2021185273A1 (zh) 靶向Sirpα的抗体或其抗原结合片段及其制备和应用
UA112050C2 (uk) Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
CN115427446A (zh) Wnt超级激动剂
CN111320693B (zh) 抗EphA4抗体
PT2620451T (pt) Métodos para inibir a ligação da endosialina a ligandos
EP4269437A1 (en) Pd-1 binding molecule and application thereof
US20220340657A1 (en) Antibody and bispecific antibody targeting lag-3 and use thereof
CN109475625A (zh) 用于治疗脊髓性肌肉萎缩症的组合物和方法
JPWO2020026987A1 (ja) 抗ｒｏｒ１モノクローナル抗体およびその機能的断片、遺伝子、薬剤デリバリー組成物、並びに、医薬組成物
US12195539B2 (en) Anti-human CD89 antibodies and uses thereof
UA111954C2 (uk) Білки зв'язування антигену
KR102800024B1 (ko) 항-ｍｙｌ9 항체
WO2017206840A1 (zh) Etar抗体，其药物组合物及其应用
US20230212306A1 (en) Anti-human tlr7 antibody
CN104693306B (zh) 一种人鼠嵌合单克隆抗体及其制备方法和应用
KR102667026B1 (ko) 항 cldn-5 항체, 및 그 항체를 함유하는 의약
AU2013297478B2 (en) Monoclonal antibody against human midkine
AU2019284320A1 (en) APJ antibody, fusion protein thereof with Elabela, and pharmaceutical compositions and use thereof
HK40119612A (zh) 用於治疗肿瘤和/或转移的抗met fab-fc
HK40075871A (en) Anti-il-22r antibodies
CN115698078A (zh) 人源化抗人cd89抗体及其用途
HK40020380A (en) Apj antibody, fusion protein thereof with elabela, and pharmaceutical compositions and use thereof